Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 6 art units • 12 examiners • 0 of 12 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
National University Corporation Kobe University is managing 12 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 12 distinct examiners and 6 distinct art units. This broad distribution suggests a diverse research portfolio with multiple independent lines of inquiry being prosecuted simultaneously.
The busiest examiner, FAIRCHILD, MALLIKA DIPAYAN, is currently handling 1 pending office action. Each of the distinct examiners is responsible for only 1 action, meaning the university's workload is completely decentralized. Managing this portfolio requires coordinating with the different examiners across 6 art units, which may lead to varied prosecution outcomes across the different biotechnology sectors.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (17%) |
| §103 only | 1 (8%) |
| §112 only | 2 (17%) |
| Double-patenting only | 1 (8%) |
| Double-patenting + other | 2 (17%) |
| Multi-statute (no §101) | 4 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAIRCHILD, MALLIKA DIPAYAN | 1 | 79.4% | +18.4% |
| MOORE, SUSANNA | 1 | 68.1% | +31.6% |
| KUBELIK, ANNE R | 1 | 75.8% | -0.7% |
| NOAKES, SUZANNE MARIE | 1 | 73.3% | +18.2% |
| WARD, AARON DUREL | 1 | — | — |
| STEADMAN, DAVID J | 1 | 57.7% | +29.6% |
| CHONG, KIMBERLY | 1 | 72.4% | +13.0% |
| NOTTINGHAM, KYLE GREGORY | 1 | 61.7% | +31.9% |
| STOCKDALE, JESSICA NICOLE | 1 | 50.0% | +35.2% |
| ZAHORIK, AMANDA MARY | 1 | 57.8% | +49.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18868907 | ORAL MUSCLE TRAINING INSTRUMENT AND ORAL MUSCLE TRAINING METHOD | FAIRCHILD, MALLIKA DIPAYAN | — |
| 18292565 | RAS/RAF BINDING INHIBITOR COMPOUND | MOORE, SUSANNA | — |
| 18741424 | METHOD FOR SELECTING PROMOTER THAT FUNCTIONS IN ORGANELLE | KUBELIK, ANNE R | — |
| 18550777 | CANCER THERAPY | CHONG, KIMBERLY | — |
| 18548008 | SEMI-RATIONAL GENOME EVOLUTION ENGINEERING METHOD FOR PLANTS | STOCKDALE, JESSICA NICOLE | — |
| 18259831 | GENE FUNCTION CONTROL BY NOVEL GUIDE NUCLEIC ACID MECHANISM | POLIAKOVA-GEORGAN, EKATERINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18634640 | COMPLEX FOR GENOME EDITING HAVING STABILITY AND FEW SIDE-EFFECTS, AND NUCLEIC ACID CODING SAME | NOAKES, SUZANNE MARIE | 7d |
| 18278498 | NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN | ZAHORIK, AMANDA MARY | 27d |
| 18539833 | METHOD FOR CONVERTING NUCLEIC ACID SEQUENCE OF CELL SPECIFICALLY CONVERTING NUCLEIC ACID BASE OF TARGETED DNA USING CELL ENDOGENOUS DNA MODIFYING ENZYME, AND MOLECULAR COMPLEX USED THEREIN | STEADMAN, DAVID J | 71d |
| 18868907 | ORAL MUSCLE TRAINING INSTRUMENT AND ORAL MUSCLE TRAINING METHOD | FAIRCHILD, MALLIKA DIPAYAN | — |
| 18292565 | RAS/RAF BINDING INHIBITOR COMPOUND | MOORE, SUSANNA | — |
| 18550777 | CANCER THERAPY | CHONG, KIMBERLY | — |
| 18547918 | METHOD FOR EVALUATING AN ABILITY OF A TEST SAMPLE TO TRIGGER A FOREIGN BODY REACTION IN THE SKIN, A METHOD FOR SCREENING A SUBSTANCE HAVING AN ABILITY TO INHIBIT A FOREIGN BODY REACTION IN THE SKIN, AND AN AGENT FOR INHIBITING A FOREIGN BODY REACTION IN THE SKIN | NOTTINGHAM, KYLE GREGORY | — |
| 18548008 | SEMI-RATIONAL GENOME EVOLUTION ENGINEERING METHOD FOR PLANTS | STOCKDALE, JESSICA NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1636 | 3 |
| 1663 | 2 |
| 1656 | 2 |
| 3792 | 1 |
| 1621 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18868907 | ORAL MUSCLE TRAINING INSTRUMENT AND ORAL MUSCLE TRAINING METHOD | FAIRCHILD, MALLIKA DIPAYAN | 3792 | §101§102§103 | Non-Final OA | — | Pending | Nov 25, 2024 |
| 18292565 | RAS/RAF BINDING INHIBITOR COMPOUND | MOORE, SUSANNA | — | §102§103§112 | Non-Final OA | — | Pending | Oct 11, 2024 |
| 18741424 | METHOD FOR SELECTING PROMOTER THAT FUNCTIONS IN ORGANELLE | KUBELIK, ANNE R | 1663 | §101§102§103§112 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18634640 | COMPLEX FOR GENOME EDITING HAVING STABILITY AND FEW SIDE-EFFECTS, AND NUCLEIC ACID CODING SAME | NOAKES, SUZANNE MARIE | 1656 | DP | Final Rejection | 7d | Pending | Apr 12, 2024 |
| 18577111 | NEPHROTOXICITY REDUCING AGENT | WARD, AARON DUREL | — | §102§103§112DP | Non-Final OA | — | Pending | Jan 05, 2024 |
| 18539833 | METHOD FOR CONVERTING NUCLEIC ACID SEQUENCE OF CELL SPECIFICALLY CONVERTING NUCLEIC ACID BASE OF TARGETED DNA USING CELL ENDOGENOUS DNA MODIFYING ENZYME, AND MOLECULAR COMPLEX USED THEREIN | STEADMAN, DAVID J | 1656 | §112 | Final Rejection | 71d | Pending | Dec 14, 2023 |
| 18550777 | CANCER THERAPY | CHONG, KIMBERLY | 1636 | §102§112 | Non-Final OA | — | Pending | Sep 15, 2023 |
| 18547918 | METHOD FOR EVALUATING AN ABILITY OF A TEST SAMPLE TO TRIGGER A FOREIGN BODY REACTION IN THE SKIN, A METHOD FOR SCREENING A SUBSTANCE HAVING AN ABILITY TO INHIBIT A FOREIGN BODY REACTION IN THE SKIN, AND AN AGENT FOR INHIBITING A FOREIGN BODY REACTION IN THE SKIN | NOTTINGHAM, KYLE GREGORY | 1621 | §112 | Non-Final OA | — | Pending | Aug 25, 2023 |
| 18548008 | SEMI-RATIONAL GENOME EVOLUTION ENGINEERING METHOD FOR PLANTS | STOCKDALE, JESSICA NICOLE | 1663 | §102§103Other | Non-Final OA | — | Pending | Aug 25, 2023 |
| 18278498 | NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN | ZAHORIK, AMANDA MARY | 1636 | §103 | Final Rejection | 27d | Pending | Aug 23, 2023 |
| 18259831 | GENE FUNCTION CONTROL BY NOVEL GUIDE NUCLEIC ACID MECHANISM | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §102§112 | Non-Final OA | — | Pending | Jun 29, 2023 |
| 16838960 | GENOMIC SEQUENCE MODIFICATION METHOD FOR SPECIFICALLY CONVERTING NUCLEIC ACID BASES OF TARGETED DNA SEQUENCE, AND MOLECULAR COMPLEX FOR USE IN SAME | SU-TOBON, QIWEN NMN | 1636 | §103§112DP | Final Rejection | 89d overdue | Pending | Apr 02, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial